1. Bjelakovic G., Nikolova D., Gluud L.L., et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008; 2: CD007176.

2. Knaus H. Corporate profi le, Ciba Geigy: pushing pills and pesticides. Multinational Monitor. 1993. Available online at: http://multinationalmonitor.org/hyper/issues/1993/04/mm0493_11.html (accessed 10 July 2012).

3. Dunne M., Flood M., Herxheimer A. Clioquinol: availability and instructions for use. J. Antimicrob Chemother. 1976; 2: 21–9.

4. Hansson O. Arzneimittel-Multis und der SMON-Skandal. Berlin: Arzneimittel-Informations-Dienst GmbH; 1979.

5. Hench P.S., Kendall E.C., Slocumb C.H., et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949; 24: 181–97.

6. Pearce N. Adverse Reactions: the fenoterol story. Auckland: Auckland University Press; 2007.

17. Gøtzsche P.C. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.

18. Michaels D. Doubt is their Product. Oxford: Oxford University Press; 2008.

19. Smith S.M., Schroeder K., Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2008; 1: CD001831.

10. Tomerak A.A.T., Vyas H.H.V., Lakhanpaul M., et al. Inhaled beta2-agonists for non-specifi c chronic cough in children. Cochrane Database Syst Rev. 2005; 3: CD005373.

11. Wilkinson E.A.J., Hawke C.C. Oral zinc for arterial and venous leg ulcers. Cochrane Database Syst Rev. 1998; 4: CD001273 (updated in 2010).

12. Husain S.L. Oral zinc sulphate in leg ulcers. Lancet. 1969; 1: 1069–71.

13. Andersen L.A., Gøtzsche P.C. Naproxen and aspirin in acute musculoskeletal disorders: a doubleblind, parallel study in sportsmen. Pharmatherapeutica. 1984; 3: 535–41.

14. Jørgensen F.R., Gøtzsche P.C., Hein P, et al. [Naproxen (Naprosyn) and mobilization in the treatment of acute ankle sprains]. Ugeskr Læger. 1986; 148: 1266–8.

15. Allen C., Glasziou P., Del Mar C. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet. 1999; 354: 1229–33.

16. Gøtzsche P.C. Bias in double-blind trials. Dan Med Bull. 1990; 37: 329–36.

17. Gøtzsche P.C. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. J Clin Epidemiol. 1990; 43: 1313–18.

18. Gøtzsche P.C. Review of dose-response studies of NSAIDs in rheumatoid arthritis. Dan Med Bull. 1989; 36: 395–9.

19. Lopez B.L., Flenders P., Davis-Moon L. Clinically signifi cant differences in the visual analog pain scale in acute vasoocclusive sickle cell crisis. Hemoglobin. 2007; 31: 427–32.

20. Gøtzsche P.C. Non-steroidal anti-infl ammatory drugs. Clinical Evidence. 2004; 12: 1702–10.

21. Rost P. The Whistleblower: confessions of a healthcare hitman. New York: Soft Skull Press; 2006.

22. Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995.

23. Henry D., Lim L.L., Garcia Rodriguez L.A., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996; 312: 1563–6.

24. Virapen J. Side Effects: death. College Station: Virtualbookworm.com Publishing; 2010.

25. Joyce C., Lesser F. Opren deaths kept secret, admits Lilly. New Sci. 1985; 107: 15–16.

26. Cotter J. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ. 2005; 172: 1299.